Mesoblast ((MESO)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Mesoblast is conducting a clinical study titled ‘A Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Combined With HA in Subjects With Moderate to Severe Chronic Low Back Pain.’ The study aims to assess the effectiveness and safety of rexlemestrocel-L combined with hyaluronic acid (HA) in reducing chronic low back pain over 12 months. This research is significant as it could offer a new treatment option for individuals suffering from degenerative disc disease.
Intervention/Treatment: The study tests an experimental treatment involving a single injection of rexlemestrocel-L combined with HA. Rexlemestrocel-L is a cell-based therapy intended to alleviate pain by being injected into a lumbar intervertebral disc, while HA is used to enhance the injection’s efficacy.
Study Design: This Phase 3 study is interventional, with participants randomly assigned to either the treatment group receiving rexlemestrocel-L + HA or a control group receiving a saline solution. The study employs a parallel intervention model and is double-blind, meaning both participants and investigators are unaware of group assignments. The primary goal is treatment-focused.
Study Timeline: The study began on March 15, 2024, with the primary completion date yet to be announced. The latest update was submitted on August 26, 2025. These dates are crucial as they mark the progress and current status of the study, indicating ongoing recruitment and data collection.
Market Implications: The update on this study could positively influence Mesoblast’s stock performance and investor sentiment, as successful results may lead to a new marketable treatment for chronic low back pain. This development is particularly relevant in the competitive landscape of pain management solutions, where innovative therapies are in high demand.
The study is ongoing, and further details are available on the ClinicalTrials portal.